FI20115640A0 - Yhdistelmähoito - Google Patents
YhdistelmähoitoInfo
- Publication number
- FI20115640A0 FI20115640A0 FI20115640A FI20115640A FI20115640A0 FI 20115640 A0 FI20115640 A0 FI 20115640A0 FI 20115640 A FI20115640 A FI 20115640A FI 20115640 A FI20115640 A FI 20115640A FI 20115640 A0 FI20115640 A0 FI 20115640A0
- Authority
- FI
- Finland
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20115640A FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Yhdistelmähoito |
| CN201280040838.2A CN103781514A (zh) | 2011-06-22 | 2012-06-15 | 联合疗法 |
| JP2014516405A JP6001655B2 (ja) | 2011-06-22 | 2012-06-15 | 併用療法 |
| CA2839807A CA2839807A1 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
| EP12767025.5A EP2723450B1 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
| DK12767025.5T DK2723450T3 (en) | 2011-06-22 | 2012-06-15 | combination therapy |
| US14/128,342 US9476050B2 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
| PCT/FI2012/050618 WO2012175798A2 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20115640A FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Yhdistelmähoito |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI20115640A0 true FI20115640A0 (fi) | 2011-06-22 |
Family
ID=44206849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20115640A FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Yhdistelmähoito |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9476050B2 (fi) |
| EP (1) | EP2723450B1 (fi) |
| JP (1) | JP6001655B2 (fi) |
| CN (1) | CN103781514A (fi) |
| CA (1) | CA2839807A1 (fi) |
| DK (1) | DK2723450T3 (fi) |
| FI (1) | FI20115640A0 (fi) |
| WO (1) | WO2012175798A2 (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10094834B2 (en) | 2012-08-30 | 2018-10-09 | Turun Yliopisto | Method of selecting individualized brain cancer therapy |
| US9663789B2 (en) * | 2013-04-26 | 2017-05-30 | Medical Diagnostic Laboratories, Llc | PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| EP3389696B1 (en) | 2015-12-17 | 2024-11-27 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| WO2017177148A1 (en) | 2016-04-07 | 2017-10-12 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| AU2003290083A1 (en) * | 2002-08-13 | 2004-03-11 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas |
| WO2004028471A2 (en) | 2002-09-28 | 2004-04-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US20040077083A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| US20040077084A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| ES2440284T3 (es) * | 2002-11-14 | 2014-01-28 | Thermo Fisher Scientific Biosciences Inc. | ARNip dirigido a tp53 |
| US20090182134A1 (en) * | 2002-11-14 | 2009-07-16 | Dharmacon, Inc. | siRNA targeting phosphatases |
| EP1618217A4 (en) | 2003-04-25 | 2008-11-26 | Dana Farber Cancer Inst Inc | BCL2L12 polypeptides and inhibitors |
| US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| WO2005011598A2 (en) | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
| GB0612542D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
| US20090274682A1 (en) | 2008-02-05 | 2009-11-05 | The Trustees Of Princeton University | Demethylation and inactivation of protein phosphatase 2a |
| TW201032796A (en) | 2009-02-04 | 2010-09-16 | Bipar Sciences Inc | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor |
-
2011
- 2011-06-22 FI FI20115640A patent/FI20115640A0/fi not_active Application Discontinuation
-
2012
- 2012-06-15 JP JP2014516405A patent/JP6001655B2/ja not_active Expired - Fee Related
- 2012-06-15 EP EP12767025.5A patent/EP2723450B1/en not_active Not-in-force
- 2012-06-15 US US14/128,342 patent/US9476050B2/en not_active Expired - Fee Related
- 2012-06-15 CN CN201280040838.2A patent/CN103781514A/zh active Pending
- 2012-06-15 WO PCT/FI2012/050618 patent/WO2012175798A2/en not_active Ceased
- 2012-06-15 CA CA2839807A patent/CA2839807A1/en not_active Abandoned
- 2012-06-15 DK DK12767025.5T patent/DK2723450T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140135377A1 (en) | 2014-05-15 |
| JP2014523426A (ja) | 2014-09-11 |
| WO2012175798A3 (en) | 2013-04-11 |
| JP6001655B2 (ja) | 2016-10-05 |
| WO2012175798A2 (en) | 2012-12-27 |
| EP2723450A2 (en) | 2014-04-30 |
| DK2723450T3 (en) | 2016-07-04 |
| US9476050B2 (en) | 2016-10-25 |
| EP2723450B1 (en) | 2016-05-18 |
| CA2839807A1 (en) | 2012-12-27 |
| CN103781514A (zh) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2663304A4 (en) | COMBINATION THERAPY | |
| HUE040564T2 (hu) | Kombinációs ischemia terápia | |
| EP2864360A4 (en) | TARGETED THERAPEUTICS | |
| DK2744810T4 (da) | Tenofovir-alafenamid-hemifumarat | |
| EP2726095A4 (en) | COMBINATION THERAPY | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| DK2769050T3 (da) | Propsensor | |
| FI20115876A0 (fi) | Yhdistelmähoito | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| EP2765427A4 (en) | Probe unit | |
| BR112014000879A2 (pt) | deflegmador | |
| DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| EP2701512A4 (en) | Aldosterone synthase inhibitors | |
| DK3141251T3 (da) | Koloskopi - forberedelse | |
| CO6970601A2 (es) | Nueva combinación | |
| EP2663189A4 (en) | Combination | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| BR112014000742A2 (pt) | terapia de combinação de als | |
| CO6880064A2 (es) | Métodos terapéuticos | |
| DE112011104936A5 (de) | Stanzstauchniet | |
| FI20115640A0 (fi) | Yhdistelmähoito | |
| DE112012000958A5 (de) | Handsäge | |
| EP2698098A4 (en) | campimeter | |
| DK2476953T3 (da) | Fluidbedkedel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |